0001213900-24-036993 Sample Contracts

COLLABORATIVE RESEARCH AGREEMENT

Collaborative Research Agreement • April 29th, 2024 • 20/20 GeneSystems, Inc. • Services-testing laboratories

• Contract Type
  Collaborative Research Agreement
• Filed
  April 29th, 2024
• Company
  20/20 GeneSystems, Inc.
• Industry
  Services-testing laboratories

This Collaborative Research Agreement (“Agreement”), effective as of Effective Date as defined in the License Agreement referenced in Recital C (the “Effective Date”) is made by and between The University of Texas M. D. Anderson Cancer Center, (“MD Anderson”), a member institution of The University of Texas System (“System”), with a place of business at 1515 Holcombe Blvd., Houston, Texas, 77030, and 20/20 GeneSystems Inc., a corporation with a place of business at 15810 Gaither Drive, Suite 235, Gaithersburg, MD 20877 (“Sponsor”). MD Anderson and Sponsor hereinafter may be referred to each as a “Party” and collectively as the “Parties.”

CONVERTIBLE BONDS SUBSCRIPTION AGREEMENT

Convertible Bonds Subscription Agreement • April 29th, 2024 • 20/20 GeneSystems, Inc. • Services-testing laboratories • New York

• Contract Type
  Convertible Bonds Subscription Agreement
• Filed
  April 29th, 2024
• Company
  20/20 GeneSystems, Inc.
• Industry
  Services-testing laboratories
• Jurisdiction
  New York

This Convertible Bonds Subscription Agreement, dated as of March 20, 2024 (this “Agreement”), is entered into by and between 20/20 GeneSystems, Inc., a Delaware corporation having its main office at 15810 Gaither Dr., Suite 235, Gaithersburg, Maryland, U.S.A. (the “Company”), and Cornerstone Investment Inc., a Korean corporation having its registered office at 21F S-Tower, 82 Saemunan-ro, Jongno-gu, Seoul, Korea (the “Investor”).

Option Agreement

Option Agreement • April 29th, 2024 • 20/20 GeneSystems, Inc. • Services-testing laboratories

• Contract Type
  Option Agreement
• Filed
  April 29th, 2024
• Company
  20/20 GeneSystems, Inc.
• Industry
  Services-testing laboratories

This Option Agreement (“Agreement”) is made as of the date of the last authorized signature below (the “Effective Date”), by and between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas, whose address is 210 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas M. D. Anderson Cancer Center (“MD Anderson”), a member institution of System, and 20/20 GeneSystems Inc., having a principal place of business located at 15810 Gaither Drive, Suite 235, Gaithersburg MD 20877 (“Company”).